3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Vomiting
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Solitary Fibrous Tumors
1
Solid Tumours
1
Sarcoma
1
Postoperative Nausea and Vomiting
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Liposarcoma
1
Leukemia, Hairy Cell
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Breast Carcinoma In Situ
1
Adenocarcinoma, Mucinous
1
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
Famotidine
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts